Cargando…

Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies

INTRODUCTION: The real-world effectiveness of belimumab for systemic lupus erythematosus (SLE) in six countries was evaluated in the OBSErve program. The aim of this post hoc analysis (GSK study 206351) was to pool individual patient OBSErve data to further evaluate the effectiveness of belimumab in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Collins, Christopher E., Cortes-Hernández, Josefina, Garcia, Mercedes A., von Kempis, Johannes, Schwarting, Andreas, Touma, Zahi, Kurtinecz, Milena, Gairy, Kerry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695800/ https://www.ncbi.nlm.nih.gov/pubmed/33206344 http://dx.doi.org/10.1007/s40744-020-00243-2

Ejemplares similares

Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies
por: Bangert, Elvira, et al.
Publicado: (2019)

Evaluating the Use of Glucocorticoids Among Belimumab‐Treated Patients With Systemic Lupus Erythematosus in Real‐World Settings Using the Rheumatology Informatics System for Effectiveness Registry
por: Hammam, Nevin, et al.
Publicado: (2022)

Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study
por: Touma, Zahi, et al.
Publicado: (2017)

Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015)

Belimumab in Systemic Lupus Erythematosus
por: Srivastava, Ankita
Publicado: (2016)

Budget Impact Analysis Of Subcutaneous Belimumab In Patients With Systemic Lupus Erythematosus In Spain
por: Cevey, Maria, et al.
Publicado: (2019)

Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus
por: Schwarting, A, et al.
Publicado: (2016)

Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
por: Plüß, Marlene, et al.
Publicado: (2022)

Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus
por: Dimelow, Richard, et al.
Publicado: (2020)

Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab
por: Guzman, Marla, et al.
Publicado: (2020)

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus
por: Urowitz, Murray B., et al.
Publicado: (2022)

Real-World Effectiveness of Belimumab in Systemic Lupus Erythematosus: A Systematic Literature Review
por: Huang, Shirley P., et al.
Publicado: (2022)

Belimumab: First targeted biological treatment for systemic lupus erythematosus
por: Dubey, Ashok K., et al.
Publicado: (2011)

Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus
por: Al Rayes, Hanan, et al.
Publicado: (2014)

First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study
por: Schwarting, Andreas, et al.
Publicado: (2016)

Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded DNA–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus
por: Doria, A., et al.
Publicado: (2018)

A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus
por: Doria, A, et al.
Publicado: (2018)

MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab cOhOrt and JapaN Lupus NatIonwide reGistry (LUNA) coHorT
por: Sada, Kenei, et al.
Publicado: (2022)

Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus
por: Zhou, Xuan, et al.
Publicado: (2021)

Belimumab in childhood systemic lupus erythematosus: A review of available data
por: Chen, Feng, et al.
Publicado: (2022)

Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment
por: Kirou, Kyriakos A., et al.
Publicado: (2022)

Safety of belimumab in adult patients with systemic lupus erythematosus: Results of a large integrated analysis of controlled clinical trial data
por: Wallace, Daniel J, et al.
Publicado: (2022)

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
por: van Vollenhoven, Ronald F, et al.
Publicado: (2012)

Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2020)

Efficacy and safety of belimumab during maintenance therapy in patients with systemic lupus erythematosus
por: Miyazaki, Yusuke, et al.
Publicado: (2021)

The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review
por: Abid, Naushad, et al.
Publicado: (2023)

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled Study
por: Stohl, William, et al.
Publicado: (2017)

Impact of Belimumab on Patient-Reported Outcomes in Systemic Lupus Erythematosus: Insights from Clinical Trials and Real-World Evidence
por: Gomez, Alvaro, et al.
Publicado: (2023)

An update on belimumab for the treatment of lupus
por: Thanou-Stavraki, Aikaterini, et al.
Publicado: (2011)

Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab
por: Roth, D A, et al.
Publicado: (2015)

Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus
por: Sheikh, Saira Z., et al.
Publicado: (2016)

Systemic Lupus Erythematosus-Associated Serositis Managed With Intravenous Belimumab: A Case Report
por: Mukkera, Srikanth, et al.
Publicado: (2022)

Short‐term clinical observations of belimumab in the treatment of recently diagnosed systemic lupus erythematosus
por: Wu, Chunye, et al.
Publicado: (2022)

Cumulative Corticosteroid Dose Over Fifty‐Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials
por: van Vollenhoven, Ronald F., et al.
Publicado: (2016)

Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE
por: Struemper, Herbert, et al.
Publicado: (2022)

Autoimmune Lupus Enteritis with Pan Gastrointestinal Involvement in an Adult Patient with Systemic Lupus Erythematosus: Complete Response to Belimumab
por: Shaik, Mohammed R., et al.
Publicado: (2023)

Health Technology Assessment of Belimumab: A New Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
por: Specchia, Maria Lucia, et al.
Publicado: (2014)

Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus
por: Yamada, Masanori, et al.
Publicado: (2013)

BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus
por: Shin, Woori, et al.
Publicado: (2018)

Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents
por: Wise, Leanna M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vpbf34qupnin2uag63fpn8jujs